This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

10 Aug 2021

Heraeus completes additional production line for platinum-based HPAPIs

The expansion is Heraeus’ response to increasing global demand for these products in cancer treatment

Three years since announcing it was expanding its production capacities for platinum-based highly potent APIs (Pt HPAPIs), Heraeus Pharmaceutical Ingredients, a business line of Heraeus Precious Metals, has finally brought the additional production line into operation.

Work began on this expansion project back in June 2018, with the company originally stating it expected to have construction completed within a year and full production capacity in 2020.

The multi-million Euro investment at the company's headquarters in Hanau, Germany, was its response to a sustained global increase in demand for Pt HPAPIs, which are important resources in treating cancer, especially in combination therapies, and are used to combat diseases such as lung cancer, colorectal cancer, ovarian cancer, and testicular cancer.

Heraeus said that having successfully validated the new production line, it can now significantly increase its manufacturing output to help in the fight against cancer.

According to Marcus Hannakam, Head of Pharmaceutical Ingredients at Heraeus, the additional capacity also means customers can benefit from quicker delivery times.

Mentioned Companies
Heraeus Deutschland GmbH & Co. KG
View company profile

Related News